Skip to main content

Table 2 Recommendation summary table

From: Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)

  Level of evidence Strength of recommendation
Environmental hygiene prevention II A
Efficacy and safety of palivizumab prevention II A
Dose of 15 mg/Kg once a month for 5 months II A
Prophylaxis in subjects with <29 weeks GA and aged ≤ 12 months at the beginning of epidemic season II A
Prophylaxis in subjects with 29–35 weeks GA and aged ≤ 6 months at the beginning of epidemic season IV B
Palivizumab prophylaxis in infants with bronchopulmonary dysplasia and aged ≤ 12 months at the beginning of epidemic season, and during the second year of life in children who require medical therapy II A
Prophylaxis in infants with severe congenital heart disease and aged ≤ 12 months at the beginning of epidemic season II A
Prophylaxis in infants with cystic fibrosis, Down syndrome, congenital diaphragmatic hernia, neuromuscular diseases, immunodeficiency, accumulation disorders, esophageal atresia, lung transplantation V B